Background And Aim: Teduglutide is a glucagon-like peptide-2 analogue used to promote intestinal rehabilitation and decrease the dependence from intravenous supplementation (IVS) in patients with short bowel syndrome and intestinal failure (SBS-IF). The aim of this study was to gain a better understanding of international real-world Teduglutide use since its launch.
Methods: Data from an international multicenter database for chronic IF were analysed. All the adult patients with SBS-IF included by centers that treated at least one patient with Teduglutide during the study period (2015-2022) were investigated. The baseline characteristics and the outcome of patients treated with Teduglutide (n.269) were compared to those of patients not receiving the drug (Controls, n.3081). The center experience was categorized based on the number of patients treated with Teduglutide: <10 or ≥10.
Results: Teduglutide cohort exhibited higher male prevalence, younger age, longer duration of HPN, higher percentage of SBS with jejunocolonic anastomosis, lower IVS volume, improved oral intake, and higher percentage of patients weaned from IVS. Controls showed higher percentages of patients deceased or lost to follow up. Centers with ≥10 patients treated with Teduglutide showed higher weaning rates and lower mortality rates.
Conclusions: This is the largest analysis of Teduglutide's real-world setting in SBS-IF. Clinicians preferentially selected for treatment patients with better prognostic indicators. Outcomes were significantly better in centers with higher Teduglutide treatment volumes, emphasizing the need for specialized referral centers to optimize care for SBS-IF patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clnu.2025.01.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic intestinal failure knowledge among a cohort of ASPEN registered dietitians: Response to a membership survey.
Nutr Clin Pract
March 2025
Intestinal Rehabilitation & Transplant Program, Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, New York, New York, USA.
Background: Rare and nutritionally complex diseases, like chronic intestinal failure (CIF), are not encountered regularly by clinicians. Specialized centers with experience in intestinal failure are relatively sparse, leading many patients to rely on local clinicians. Previously published reports demonstrated lack of knowledge in intestinal failure among gastroenterologists in the United States, in Europe, and in the United Kingdom.
View Article and Find Full Text PDFMeconium ileus (MI) is the result of the accumulation of thick, dry, inspissated meconium that creates a bowel blockage, most commonly in the terminal ileum. These pockets of meconium prevent passage of stool beyond the point of obstruction, which leads to distention of the proximal bowel, bowel wall thickening, and distal microcolon. Occurring most commonly (90%) in conjunction with cystic fibrosis (CF), the occurrence of MI without CF is rare.
View Article and Find Full Text PDFPreventive effect of quinoa polysaccharides on lipopolysaccharide-induced inflammation in mice through gut microbiota regulation.
Int J Biol Macromol
March 2025
Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology & Business University, Beijing 100048, China. Electronic address:
Inflammation significantly influences the development of gastrointestinal (GI) diseases such as inflammatory bowel diseases (IBD)and ulcerative colitis, which disrupts normal digestive functions, leading to tissue damage and various symptoms. This research explores the preventive effects of quinoa polysaccharides (QPS) on lipopolysaccharide (LPS)-induced systemic acute inflammation in mice and their mechanism of action. The findings revealed that QPS alleviated LPS-induced inflammation symptoms, enhanced the mice behavior score and their immune organ index, reduced pro-inflammatory cytokines (IL-6, TNF-α and IL-1β) levels, elevated the expression level of tight junction proteins (ZO-1, MUC2).
View Article and Find Full Text PDFUsing gut microbiota and non-targeted metabolomics techniques to study the effect of xylitol on alleviating DSS-induced inflammatory bowel disease in mice.
BMC Immunol
March 2025
Department of Laboratory Medicine, Taizhou Second People's Hospital, Taizhou, 225309, China.
Background: Inflammatory bowel disease (IBD) has become a global healthcare issue, with its incidence continuing to rise, but currently there is no complete cure. Xylitol is a widely used sweetener in various foods and beverages, but there is limited research on the effects of xylitol on IBD symptoms.
Aim: Study on the effect of oral xylitol in improving intestinal inflammation and damage in IBD mice, further explore the mechanism of xylitol in alleviating IBD symptoms using intestinal microbiota and non-targeted metabolomics techniques.
Relating the molecular phenotype of ulcerative colitis to the clinical course.
Sci Rep
March 2025
Department of Medicine, Division of Gastroenterology, University of Alberta, 8540 - 112 Street NW, Edmonton, AB, T6G 2X8, Canada.
The expanding portfolio of targeted therapies for ulcerative colitis (UC) suggests that a more precise approach to defining disease activity will aid clinical decision-making. This prospective study used genome-wide microarrays to characterize gene expression in biopsies from the most inflamed colon segments from patients with UC and analyzed associations between molecular changes and short-term outcomes while on standard-of-care treatment. We analyzed 141 biopsies-128 biopsies from 112 UC patients and 13 biopsies from eight inflammatory bowel disease unclassified (IBDU) patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!